Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spikogen COVID-19 vaccine in vaccine-naïve adults
NCT05279456Phase 3Completed
- Sponsor
- Vaxine
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SpikoGen in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Vaxine. Primary endpoints: Seroconversion Rate at 7 months, Geometric Mean Titer at 7 months and 2 more. Started Aug 2022; status: completed.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05279456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279456.